A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers-Reference-Cited by-同舟云学术

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers

Published:2020 Issue: Volume:93 Page:100604
ISSN:0011-393X
Container-title:Current Therapeutic Research
language:en
Short-container-title:Current Therapeutic Research

Author:

Printz Marie A.,Dychter Samuel S.,DeNoia Emanuel P.,Harrigan Rena,Sugarman Barry J.,Zepeda Monica^ORCID,Souratha Jennifer,Kang David W.,Maneval Daniel C.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference36 articles.

1. Use of hyaluronidase with local anesthesia in ophthalmology: preliminary report;Atkinson;Arch Ophthalmol,1949

2. Hyaluronan as a therapeutic target in human diseases;Liang;Adv Drug Deliv Rev,2016

3. The impact of extracellular matrix on the chemoresistance of solid tumors–experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy;Baumgartner;Cancer Lett,1998

4. Hyaluronidase: A review of approved formulations, indications and off-label use in chronic pain management;Dunn;Expert Opin Biol Ther,2010

5. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration;Frost;Expert Opin Drug Deliv,2007

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Potential Role of Phytopharmaceuticals in Alleviating Toxicities of Chemotherapeutic Agents;Current Protein & Peptide Science;2024-12

2. Hyaluronidase overcomes the extracellular matrix barrier to enhance local drug delivery;European Journal of Pharmaceutics and Biopharmaceutics;2024-10

3. The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies;Journal of Controlled Release;2024-10

4. Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology;Advanced Materials;2024-08-20

5. Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants;Journal of Clinical Immunology;2024-06-19